Body Protection Compound-157. A synthetic 15-amino acid pentadecapeptide derived from a protective protein isolated from human gastric juice. Extensively researched for its role in angiogenesis, tendon-to-bone healing, and mucosal protection.
BPC-157 is a pleiotropic compound with activity across multiple biological systems. Current research suggests the following primary mechanisms, based on in vitro and in vivo animal model data:
BPC-157 significantly upregulates vascular endothelial growth factor receptor 2 (VEGFR2), driving angiogenic processes in healing tissue. This accelerates the formation of new capillary networks essential for tissue repair and oxygen delivery to ischemic areas.
The peptide modulates nitric oxide synthesis, demonstrating cytoprotective effects particularly in the gastrointestinal tract. This NO-dependent pathway underlies much of BPC-157's gastroprotective activity observed in gastric ulcer models.
In tendon and ligament research models, BPC-157 upregulates growth hormone receptors (GHR) at the site of injury, enhancing GH-mediated repair signalling locally without systemic GH elevation. This contributes to accelerated tendon-to-bone healing observed in animal studies.
BPC-157 upregulates epidermal growth factor (EGF) and its receptor (EGFR), supporting mucosal regeneration in the GI tract. Studies by Sikirić et al. document significant acceleration of mucosal healing in rat models with chemically induced damage.
In vitro research demonstrates BPC-157 activates the focal adhesion kinase (FAK)–paxillin signalling axis, accelerating fibroblast and myoblast migration toward injury sites — a critical component in organised tissue repair.
Primary references: Sikirić PC et al. (2018). "Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157." Current Pharmaceutical Design 24(18):1990–2001. DOI:10.2174/1381612824666180inclination. Chang CH et al. (2011). "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol 110(3):774–780.
BPC-157 has been among the most studied synthetic peptides in orthopaedic research contexts. Animal model studies (Sprague-Dawley rats, New Zealand white rabbits) consistently demonstrate accelerated healing in Achilles tendon transection, medial collateral ligament transection, and rotator cuff tear models. Chang et al. (2011) reported statistically significant improvements in structural organisation and biomechanical tensile strength in BPC-157-treated tendons compared to controls at 8-week follow-up.
The peptide's gastric origin correlates with extensive GI research. Studies from Sikirić's group at the University of Zagreb have documented protective and healing effects in models of NSAID-induced gastric ulceration, anastomotic healing, and short bowel syndrome in rodents. The cytoprotection appears to operate independently of acid suppression — a mechanistically distinct property from conventional gastroprotective agents.
Emerging preclinical research explores BPC-157's modulatory effects on the dopaminergic and serotonergic systems. Rodent studies have investigated its activity in models of depression (forced swim test, tail suspension test), with observed effects on dopamine receptor expression in the nucleus accumbens. This remains an active and early-stage area of investigation.
BPC-157 has demonstrated significant anti-inflammatory properties in carrageenan-induced paw oedema models and in adjuvant arthritis models, apparently without classical COX-2 inhibition — suggesting an alternative mechanism potentially involving JAK-STAT or NF-κB pathway modulation. Further in vitro mechanistic work is needed to confirm the precise targets.
The majority of BPC-157 research to date has been conducted in rodent models. Human clinical trial data is limited. Researchers and institutions should review the primary literature independently and apply appropriate experimental controls.
Full HPLC chromatogram, mass spectrum, and identity confirmation. Issued by independent accredited laboratory. Available on request within 24 hours.
| Test Parameter | Specification | Result | Status |
|---|---|---|---|
| Identity (ESI-MS) | m/z consistent with MW 1419.5 Da | 1419.48 Da | ✓ Pass |
| Purity (RP-HPLC) | ≥99.0% | 99.5% | ✓ Pass |
| Water content (KF) | ≤8.0% | 4.2% | ✓ Pass |
| Appearance | White to off-white lyophilised powder | Confirmed | ✓ Pass |
| Heavy metals (ICP) | ≤10 ppm total | <2 ppm | ✓ Pass |
1 mL BAC water + 5 mg BPC-157 = 5,000 mcg/mL (5 mg/mL). For 500 mcg/dose: 0.1 mL per administration in animal models.
HPLC-verified ≥99.5% purity. Available as 5 mg lyophilised vial or 500 mcg capsules. Independent COA available on request. For laboratory research use only.